First Department of Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo- ku, Hamamatsu, Shizuoka, 431-3192, Japan.
Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka, 431-3192, Japan.
Lipids Health Dis. 2024 May 25;23(1):154. doi: 10.1186/s12944-024-02121-0.
Cancer prognosis remains a critical clinical challenge. Lipidomic analysis via mass spectrometry (MS) offers the potential for objective prognostic prediction, leveraging the distinct lipid profiles of cancer patient-derived specimens. This review aims to systematically summarize the application of MS-based lipidomic analysis in prognostic prediction for cancer patients. Our systematic review summarized 38 studies from the past decade that attempted prognostic prediction of cancer patients through lipidomics. Commonly analyzed cancers included colorectal, prostate, and breast cancers. Liquid (serum and urine) and tissue samples were equally used, with liquid chromatography-tandem MS being the most common analytical platform. The most frequently evaluated prognostic outcomes were overall survival, stage, and recurrence. Thirty-eight lipid markers (including phosphatidylcholine, ceramide, triglyceride, lysophosphatidylcholine, sphingomyelin, phosphatidylethanolamine, diacylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylethanolamine, lysophosphatidic acid, dihydroceramide, prostaglandin, sphingosine-1-phosphate, phosphatidylinosito, fatty acid, glucosylceramide and lactosylceramide) were identified as prognostic factors, demonstrating potential for clinical application. In conclusion, the potential for developing lipidomics in cancer prognostic prediction was demonstrated. However, the field is still nascent, necessitating future studies for validating and establishing lipid markers as reliable prognostic tools in clinical practice.
癌症预后仍然是一个重大的临床挑战。通过质谱（MS）进行脂质组学分析有可能利用癌症患者来源标本的独特脂质谱进行客观的预后预测。本综述旨在系统总结基于 MS 的脂质组学分析在癌症患者预后预测中的应用。我们的系统综述总结了过去十年中通过脂质组学尝试预测癌症患者预后的 38 项研究。常见的分析癌症包括结直肠癌、前列腺癌和乳腺癌。液体（血清和尿液）和组织样本同样被使用，液相色谱-串联质谱是最常用的分析平台。最常评估的预后结果是总生存期、分期和复发。38 个脂质标志物（包括磷脂酰胆碱、神经酰胺、甘油三酯、溶血磷脂酰胆碱、鞘磷脂、磷脂酰乙醇胺、二酰基甘油、磷脂酸、磷脂酰丝氨酸、溶血磷脂酰乙醇胺、溶血磷脂酸、二氢神经酰胺、前列腺素、鞘氨醇 1-磷酸、磷脂酰肌醇、脂肪酸、葡萄糖神经酰胺和乳糖神经酰胺）被确定为预后因素，显示出潜在的临床应用前景。总之，在癌症预后预测中开发脂质组学的潜力得到了证明。然而，该领域仍处于起步阶段，需要进一步的研究来验证和确立脂质标志物作为临床实践中可靠的预后工具。
